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Objective. To obtain pilot data on the endometrial histology of Depomedroxyprogesterone acetate (Depo-Provera, DMPA) users
experiencing breakthrough bleeding (BTB) versus users with amenorrhea. To compare the endometrial histology of patients who
used DMPA continuously for 3–12 months versus those who used it for 13 months or more. Methods. Cross-sectional study. En-
dometrialbiopsywasobtainedfromallconsentingpatientswhousedDMPAforatleast3months.Patientsweredividedintothose
with BTB in the last 3 months versus those with amenorrhea for at least 3 months. Histology results and duration of therapy were
compared. Results. The proportion of women with chronic endometritis, uterine polyps, atrophic, proliferative, or progesterone-
dominant endometrium did not diﬀer between those DMPA users with BTB versus those with amenorrhea. Duration of therapy
did not correlate with symptoms of BTB or endometrial histology. Chronic endometritis was the most common histologic ﬁnding
(10/40, 25%) and occurred more often in women experiencing BTB (35% versus 15%) (RR 1.62 CI 0.91–2.87). Moreover, 45% of
women with BTB had received DMPA for more than 12 months. Conclusions. BTB was more common than previously reported
in women using DMPA for more than 12 months. Chronic endometritis, which may indicate an underlying infectious or intra-
cavitary anatomic etiology, has not been previously reported as a frequent ﬁnding in DMPA users, and may be related to ethnic or
other sociodemographic characteristics of our patient population. Further study to elucidate the etiology of chronic endometritis
in these patients is warranted.
Copyright © 2006 A. R. Thurman and D. E. Soper. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
INTRODUCTION
Depomedroxyprogesterone acetate (DMPA or Depo-Prov-
era) is a long-acting injectable contraceptive, approved for
use in the United States in 1992 [1–3]. DMPA has been avail-
able worldwide since the 1960s and has been used by more
than 30 million women in more than 90 countries [1–3].
This convenient contraceptive has typical failure rates that
are lower than all the other temporary, hormonal methods
andatheoreticalfailureratewhichislowerthansurgicalster-
ilization [1–3] .T h em o s tc o m m o ns i d ee ﬀect of DMPA is
breakthrough bleeding (BTB), which occurs in 70% of pa-
tients in the ﬁrst year, and in approximately 10% thereafter
[1]. Unfortunately, 25% of patients discontinue this eﬀective
contraceptive in the ﬁrst year because the bleeding is intol-
erable [4]. Therapy for irregular bleeding on DMPA has had
limited success [5, 6]. Treatment with estrogen, nonsteroidal
antiinﬂammatory drugs (NSAIDs), or more frequent DMPA
injections has been recommended by various authors, with
some of these recommendations based on treatment trials
of Norplant users and, more often, on assumptions regard-
ing the endometrial histology of DMPA users [1, 2, 5–11].
Physiciansmustoftenresorttoreassuring patients thatirreg-
ular bleeding is an expected side eﬀect, which will abate with
time. It is likely that if the underlying endometrial histology
in patients suﬀering from this side eﬀect was known, therapy
could be more directed and successful. The goal of this study
is to describe the endometrial histology of DMPA users who
areamenorrheicversusthosewhoexperienceBTBandtoob-
tain data on the endometrial histology based on duration of
continuous DMPA use.
METHODS
This is a cross-sectional study. Based on previous studies, we
predicted that 75% of amenorrheic DMPA users would have
a progesterone-dominant or atrophic endometrium com-
pared to only 25% of patients with BTB on DMPA [12, 13].
Based on these assumptions, 18 patients were required in
each group to have an 80% power to detect a 50% diﬀerence2 Infectious Diseases in Obstetrics and Gynecology
Table 1: Endometrial histology in patients with breakthrough bleeding on DMPA.
Age (y) Race (A = African




37 A 3/1 62 Polyp
42 A 3/2 60 Benign inactive
34 A 3/3 42 Benign inactive
20 C 1/1 04 Chronic endometritis
35 A 4/4 03 Chronic endometritis
25 A 1/1 06 Proliferative
21 A 1/1 03 Placental site nodule
33 C 2/1 06 Progesterone dominant
26 A 1/1 48 Progesterone dominant
28 A 2/2 24 Chronic endometritis
29 A 1/1 09 Atrophic
24 C 3/2 12 Atrophic
30 C 3/2 48 Atrophic
39 A 4/4 120 Chronic endometritis
24 A 1/1 36 Chronic endometritis
30 A 8/6 03 Chronic endometritis
21 A 1/1 18 Polyp
43 A 1/1 09 Menstrual endometrium
21 A 1/1 09 Chronic endometritis
19 A 1/1 03 Menstrual endometrium
with an alpha of 0.05. This power analysis was calculated us-
ing Epi Info 2002, CDC Software, Atlanta, Ga.
All patients presenting to the outpatient gynecology
clinic who used DMPA for at least 3 months were asked
to participate in the study. We recruited the ﬁrst 20 pa-
tients with BTB and the ﬁrst 20 patients with amenorrhea on
DMPA. This study was approved by the Institutional Review
Board at the Medical University of South Carolina.
Inclusion criteria were the ability to give informed con-
sent and use of Depo-Provera continuously for at least 3
months. BTB was deﬁned as unscheduled uterine bleeding
in the last 3 months. Amenorrhea was deﬁned as no uter-
ine bleeding for at least 3 months. Patients were excluded
if they had other possible causes of vaginal bleeding: using
other hormone medications in the last 3 months, intrauter-
ine device use, and active cervical dysplasia greater than low-
grade squamous intraepithelial neoplasia. Patients were also




Informed consent was obtained by the physician per-
forming the biopsy (AT). The duration of uninterrupted
DMPA use, in months, and the patient’s age, race, gravid-
ity, and parity were recorded. The patient’s pap smear and
cervical tests for N gonorrhoea and Chlamydia trachomatis
withinthelastyearwereconﬁrmedtobenegativepriortothe
procedure. A wet prep was prepared to determine the pres-
ence of yeast vaginitis or bacterial vaginosis (BV). BV was
diagnosedusingAmsel’scriteria(14).Anendometrialbiopsy
was performed, using a 3mm Unimar Pipelle (Wilton,
Conn).
A pathologist, who was blinded to the patient’s clini-
cal symptoms, interpreted the endometrial biopsies. Chronic
endometritiswasdeﬁnedasgreaterthanorequalto2plasma
cells in the endometrial sample. Treatment regimens for BTB
were not investigated in this study.
Chi-square statistic and 2-tailed Fisher’s exact test were
used to compare the proportions of patients with various en-
dometrial histologies in each group.
RESULTS
The biopsy results of patients experiencing BTB on DMPA
(n = 20) are presented in Table 1. The endometrial histology
results of patients with amenorrhea on DMPA (n = 20) are
presented in Table 2. The comparison of histologic diagnoses
among women with BTB versus women with amenorrhea
are shown in Table 3. Chronic endometritis was more than
twice as common in DMPA users complaining of BTB (7/20,
35% versus 3/20, 15%) (RR 1.62 CI 0.91–2.87). The signif-
icance of this ﬁnding is limited by sample size. An atrophic,
progesterone-dominant,ornoendometriumwasmorecom-
monly found in those with amenorrhea (RR 0.50 CI 0.23–
1.10).
Because the DMPA package insert shows a signiﬁcant
decrease in BTB at the 1-year mark, we also comparedA. R. Thurman and D. E. Soper 3
Table 2: Endometrial histology in patients with amenorrhea on Depo-Provera.
Age (y) Race (A = African




48 A 4/4 48 Atrophic
39 A 4/2 03 No endometrium
23 C 0/0 15 Benign inactive
21 A 0/0 36 Chronic endometritis
37 A 0/0 26 Polyp
28 A 4/4 12 Benign inactive
32 A 3/1 15 Polyp & proliferative
38 A 1/1 36 No endometrium
27 C 1/1 18 Benign inactive
38 C 1/1 60 Progesterone dominant
22 A 1/1 12 Atrophic
36 A 6/1 09 Progesterone dominant
18 A 0/0 03 Chronic endometritis
18 A 1/1 03 Atrophic
19 A 0/0 03 Progesterone dominant
33 A 1/1 12 Atrophic
31 A 2/2 60 Progesterone dominant
29 A 3/2 27 Progesterone dominant
25 C 1/0 60 Proliferative
26 A 3/1 24 Chronic endometritis










2-tailed test P value
Chronic endometritis 7 3 .15 N/A
Atrophic or no endometrium 3 6 N/A .45
Proliferative 1 1 N/A 1.00
Progesterone dominant 2 5 N/A .40
Polyp 2 2 N/A 1.00
Benign inactive 2 3 N/A 1.00
Menstrual 2 0 N/A .49
Placental site nodule 1 0 N/A 1.00
womenwhousedDMPAcontinuouslyfor3–12months(n =
19) with women who received DMPA continuously for 13
months or longer (n = 21) in Table 4. Surprisingly, there was
no diﬀerence between the incidence of BTB among women
who had been on DMPA for less or more than 1 year, but
the analysis is limited by sample size. Also, despite the as-
sumption that women trend to a progesterone-dominant en-
dometrium over time, there was no diﬀerence in various his-
tologic diagnoses between women on DMPA for more or
less than 1 year. There was no diﬀerence in the rate of BV
among patients with BTB (5/20) versus those with amenor-
rhea (7/20) P = .49. Also, there was no diﬀerence in the in-
cidence of BV in patients with chronic endometritis (4/10)
versus those without chronic endometritis (8/30) P = .45,
but these data are limited by sample size. We did not collect
information on body mass index (BMI).
Finally, a very unusual ﬁnding was a patient with BTB
whohadaplacentalsitenodule.ShehadbeenonDMPAfor3
monthspostpartum,afteranuncomplicatedvaginaldelivery,
and her beta human chorionic gonadotropin level was zero.
Her BTB resolved within 1 month of biopsy, and no further
treatment was necessary.
DISCUSSION
This study found that women using DMPA exhibit a vari-
ety of endometrial histologic ﬁndings. Chronic endometri-
tis was a frequent ﬁnding in our patients, which has not4 Infectious Diseases in Obstetrics and Gynecology
Table 4: Comparison on symptoms and endometrial histology among women using Depo-Provera (DMPA) for 3–12 months versus those




months (n = 19)
DMPA Use 13 or more




2-tailed test P value
Breakthrough bleeding 11 9 .35 N/A
Chronic endometritis 5 5 N/A 1.00
Atrophic or no endometrium 6 3 N/A .26
Proliferative 1 1 N/A 1.00
Progesterone dominant 3 4 N/A 1.00
Polyp 0 4 N/A .11
Benign inactive 1 4 N/A .35
Menstrual 2 0 N/A .22
Placental site nodule 1 0 N/A .48
been previously reported. Using various combinations of
the key words—Depomedroxyprogesterone acetate, bleed-
ing, injectable contraception, side eﬀects, endometrium, and
histology—we located 4 studies on the endometrial his-
tology of DMPA users [12–15]. Mishell et al and Karim
and colleagues performed sequential endometrial biopsies
on postpartum women given DMPA, the majority of whom
were Caucasian or Middle Eastern, and found that atrophic
or inactive endometriums prevailed with duration of DMPA
use [14, 15]. The incidence of BTB decreased with time, but
neither group correlated endometrial histology with patient
symptoms [14, 15]. Lee performed sequential endometrial
biopsies on 14 patients given DMPA postpartum and found
that patients with BTB tended to have a proliferative en-
dometrium while patients with amenorrhea had an atrophic
endometrium [12]. Jeppsson obtained endometrial biopsies
on 11 Swedish DMPA users, all of whom were amenorrheic
and had been using DMPA continuously for a mean of 36
months[13].Allofthesepatientsexhibitedmarkedendome-
trial atrophy [13].
We found chronic endometritis in 7 women with BTB
(35%) and 3 women with amenorrhea on DMPA (15%).
Chronicendometritiswasnotreportedinpreviousstudiesof
DMPA patients and may reﬂect ethnic or other demographic
factors of our study population, as BTB on DMPA has been
correlated with ethnicity [16]. Chronic endometritis has also
not been found in studies of the endometrial histology of
Mircette, Cyclofem, or Norplant users [17–19]. In a review
of endometrial bleeding, Ferenczy postulates that some en-
dometrial bleeding is the result of an inﬂammatory environ-
ment, caused by endometrial atrophy, friction between the
endometrial surfaces, and subsequent microerosions [20].
Chronic endometritis may also arise from intracavitary le-
sions such as submucosal ﬁbroids or uterine polyps. None
of our patients had clinical evidence of an active cervical in-
fection, which suggests that the chronic endometritis found
in this study was inﬂammatory rather than infectious. Our
data is limited by the fact that we relied on a negative screen-
ing test for chlamydia and gonorrhea within the year and en-
dometrial cultures were not performed. Chronic endometri-
tis has been used as a surrogate for the diagnosis of atyp-
ical pelvic inﬂammatory disease [21]. In our patient pop-
ulation, at risk for sexually transmitted infections, further
investigation regarding the etiology of chronic endometritis
is warranted.
Ourﬁndingssuggestthatantimicrobialorantiinﬂamma-
tory therapy may be the most eﬀective to treat BTB in these
patients. This new avenue of therapy for BTB in DMPA users
needs to be investigated in future studies. The treatment of
BTB on DMPA is based on assumptions of the endometrial
histology, and many of the recommendations are from data
of Norplant users with BTB [9, 10, 22]. Empiric treatment of
BTB on DMPA has had limited success [5, 6]. Estrogen ther-
apy is recommended when it is suspected that the patient has
developed a fragile, atrophic endometrium [1–3, 5, 6, 11].
More frequent DMPA injections have been advocated, but
Harelandcoworkersfoundthatthebleedingpatternsofado-
lescents who received DMPA every 6 weeks were similar to
the patterns of those whoreceived DMPAevery 12 weeks [8].
Progesterone-dominant oral contraceptives have also been
suggested to treat BTB on DMPA, which assumes the patient
hasaproliferativeendometriumwhichneedstobeconverted
to an atrophic or progesterone eﬀect pattern [1, 8]. NSAIDs
have also been advocated for BTB in DMPA users, based on
treatment studies of Norplant users [9, 10]. NSAIDs can de-
crease endogenous prostaglandins associated with BTB.
The package insert for DMPA reports that the level of
medroxyprogesteroneacetate(MPA)shouldbe1–7ng/mLat
3 weeks after the DMPA injection and < 100pg/mL at 120–
200 days postinjection. A study of Thai patients, whose aver-
age BMI was 22, found that estradiol and progesterone lev-
els were not correlated with the presence or duration of BTB
in DMPA users [23]. The serum levels of progesterone after
DMPAadministrationarehighenoughthatcontraceptiveef-
ﬁcacy is not inﬂuenced by the patient’s weight [6]. However,
DMPA does not suppress follicle stimulating hormone, and
therefore estrogen levels are comparable to the early follicu-
lar phase and will be inﬂuenced by the patient’s weight [6]. It
is possible that BMI is associated with BTB, and this should
be an area of future research.A. R. Thurman and D. E. Soper 5
It has been shown that adolescents who transition from
c o m b i n e do r a lc o n t r a c e p t i v e st oD M P Ah a v el e s sB T Bt h a n
those who begin DMPA without prior hormone exposure
[8]. It is presumed that upregulation of endometrial proges-
terone receptors by estrogen in oral contraceptives account
for this ﬁnding [8]. A previous study found that endome-
trial glandular progesterone receptor immunoreactivity was
similar in patients experiencing bleeding or amenorrhea on
DMPA[23].However,the immunoreactivity ofprogesterone
receptors in the endometrial stroma was elevated in pa-
tients with amenorrhea on DMPA, as compared to those
with bleeding on DMPA [23]. However, among patients with
bleeding on DMPA, the duration of bleeding did not corre-
late with progesterone receptor quantity, indicating that ad-
ditional processes, namely, inﬂammatory or infectious, may
be contributing to the bleeding [23].
Our pilot study was limited by the small number of pa-
tients. Our pretest power analysis, based on commonly ap-
plied assumptions regarding the endometrial histology of
DMPA users, was inaccurate. We were surprised to ﬁnd that
lessthan25%ofourpatientshadevidenceofaprogesterone-
dominant endometrium and so many of the patients had
evidence of chronic endometritis. We would require addi-
tional 134 patients to render a statistically valid evaluation
of chronic endometritis. Finally, the cross sectional design
of the study limited analysis of how the endometrial lining
c h a n g e sw i t ht i m ei nD M P Au s e r s .
In summary, this study found that DMPA users can ex-
hibit several endometrial histologic diagnoses, and the tis-
sue ﬁndings do not correlate easily with the patient’s symp-
toms or duration of medication use. Chronic endometri-
tis was the most common histologic diagnosis in women
experiencing BTB and has not previously been reported.
Chronic endometritis likely reﬂects an underlying infectious
or anatomic abnormality which would completely change
the management of BTB in these patients, and will require
furtherevaluation.Webelievefurtherstudiestoelucidatethe
etiology of BTB in DMPA users are indicated.
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